Our differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. The company was established in 2017 based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs).
Nectin Therapeutics has an established, scientific and management team with deep experience in oncology R&D, successful track record building biotech companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by our partners at aMoon Fund, Peregrine Ventures, and Integra Holdings.
A first-in-class mAb, directed against a key immune checkpoint, PVR (CD155). NTX1088 demonstrated superior antitumor activity compared to approved and investigational Immune Checkpoint Inhibitors (ICIs) in pre-clinical models. NTX1088 has a favorable safety profile in non-human primates (NHP), and IND filing is en route to support first-in-human trial initiation in Q2 2022.
A best-in-class mAb, targeting CD112R (PVRIG), a novel immune inhibitory receptor. NTX2R13 demonstrated superior therapeutic potential with an initial clean safety profile in NHP. IND submission for NTX2R13 is expected 2023. Along with their single agent activity, NTX1088 and NTX2R13 synergize with each other, and exhibit noticeable synergy with approved PD(L)1 blockers in various pre-clinical studies, raising the possibility for the development of combination immunotherapy.
Leveraging our technological platform, Nectin Therapeutics is engaged in the development of a pipeline of first-in-class and best-in-class ADC therapies. Our candidates have demonstrated robust tumor regression in multiple in vivo models of solid and hematological malignancies. Our ADC programs are currently undergoing IND-enabling studies.